CoChat
Sign Up
Cited by 34

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Precise profiling of exosomal biomarkers via programmable curved plasmonic nanoarchitecture-based biosensor for clinical diagnosis of Alzheimer's disease

Song, Sojin, Lee, Jong Uk, Jeon, Myeong Jin, Kim, Soohyun, Lee, Chan-Nyoung, Sim, Sang Jun·2023·Biosensors and Bioelectronics
DOI 10.1016/j.bios.2023.115269
Open this paper in CoChat — free account

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease of complex pathogenesis, with overt symptoms following disease progression. Early AD diagnosis is challenging due to the lack of robust biomarkers and limited patient access to diagnostics via neuroimaging and cerebrospinal fluid (CSF) tests. Exosomes present in body fluids are attracting attention as diagnostic biomarkers that directly reflect neuropathological features within the brain. In particular, exosomal miRNAs (exomiRs) signatures are involved in AD pathogenesis, showing a different expression between patients and the healthy controls (HCs). However, low yield and high homologous nature impede the accuracy and reproducibility of exosome blood-based AD diagnostics. Here, we developed a programmable curved plasmonic nanoarchitecture-based biosensor to analyze exomiRs in clinical serum samples for accurate AD diagnosis. To allow the detection of exomiRs in serum at attomolar levels, nanospaces (e.g., nanocrevice and nanocavity) were introduced into the nanostructures to dramatically increase the spectral sensitivity by adjusting the bending angle of the plasmonic nanostructure through sodium chloride concentration control. The developed biosensor classifies individuals into AD, mild cognitive impairment (MCI) patients, and HCs through profiling and quantifying exomiRs. Furthermore, integrating analysis expression patterns of multiple exosomal biomarkers improved serum-based diagnostic performance (average accuracy…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bios.2023.115269

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 5 references

Research works printed but not linked: 59

  1. Alafeef, 2020, Rapid, ultrasensitive, and quantitative detection of SARS-CoV-2 using antisense oligonucleotides directed electrochemical biosensor chip, ACS Nano, 14, 17028, 10.1021/acsnano.0c06392 · DOI
  2. Albert, 2011, The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's Dementia, 7, 270, 10.1016/j.jalz.2011.03.008 · DOI · Paper page
  3. Alivisatos, 2004, The use of nanocrystals in biological detection, Nat. Biotechnol., 22, 47, 10.1038/nbt927 · DOI
  4. Anker, 2010, Biosensing with plasmonic nanosensors, Nanosci. Technol.: Collect. Rev. Nat. J., 308
  5. Baird, 2015, Blood-based proteomic biomarkers of Alzheimer's disease pathology, Front. Neurol., 6, 236, 10.3389/fneur.2015.00236 · DOI
  6. Barbagallo, 2020, Specific signatures of serum miRNAs as potential biomarkers to discriminate clinically similar neurodegenerative and vascular-related diseases, Cell. Mol. Neurobiol., 40, 531, 10.1007/s10571-019-00751-y · DOI
  7. Bhalla, 2020, Opportunities and challenges for biosensors and nanoscale analytical tools for pandemics: COVID-19, ACS Nano, 14, 7783, 10.1021/acsnano.0c04421 · DOI
  8. Borrebaeck, 2017, Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer, Nat. Rev. Cancer, 17, 199, 10.1038/nrc.2016.153 · DOI
  9. Chung, 2018, Enhancing the performance of surface plasmon resonance biosensor via modulation of electron density at the graphene–gold interface, Adv. Mater. Interfac., 5, 10.1002/admi.201800433 · DOI
  10. Chuntonov, 2011, Trimeric plasmonic molecules: the role of symmetry, Nano Lett., 11, 2440, 10.1021/nl2008532 · DOI
  11. De, 2008, Applications of nanoparticles in biology, Adv. Mater., 20, 4225, 10.1002/adma.200703183 · DOI · Paper page
  12. Dong, 2020, DNA functional materials assembled from branched DNA: design, synthesis, and applications, Chem. Rev., 120, 9420, 10.1021/acs.chemrev.0c00294 · DOI
  13. Guo, 2016, The effect of pH on charge inversion and condensation of DNA, Soft Matter, 12, 6669, 10.1039/C6SM01344A · DOI
  14. Haberberger, 2018, Changes in the microRNA expression profile during blood storage, BMJ Open Sport Exer. Med., 4
  15. Hansson, 2019, Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease, Alzheimer's Res. Ther., 11, 1, 10.1186/s13195-019-0485-0 · DOI · Paper page
  16. Huang, 2015, Nanogap effects on near-and far-field plasmonic behaviors of metallic nanoparticle dimers, Phys. Chem. Chem. Phys., 17, 29293, 10.1039/C5CP04460J · DOI
  17. Jin, 2001, Photoinduced conversion of silver nanospheres to nanoprisms, Science, 294, 1901, 10.1126/science.1066541 · DOI
  18. Jones, 2011, Templated techniques for the synthesis and assembly of plasmonic nanostructures, Chem. Rev., 111, 3736, 10.1021/cr1004452 · DOI
  19. Kappel, 2015, MicroRNA in vitro diagnostics using immunoassay analyzers, Clin. Chem., 61, 600, 10.1373/clinchem.2014.232165 · DOI
  20. Kim, 2019, A nanoplasmonic biosensor for ultrasensitive detection of Alzheimer's disease biomarker using a chaotropic agent, ACS Sens., 4, 595, 10.1021/acssensors.8b01242 · DOI
  21. Kim, 2018, A shape-code nanoplasmonic biosensor for multiplex detection of Alzheimer's disease biomarkers, Biosens. Bioelectron., 101, 96, 10.1016/j.bios.2017.10.018 · DOI
  22. Klunk, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B, Ann. Neurol.: Off. J. Am. Neurol. Assoc. Child Neurol. Soc., 55, 306, 10.1002/ana.20009 · DOI · Paper page
  23. Koya, 2020, Novel plasmonic nanocavities for optical trapping‐assisted biosensing applications, Adv. Opt. Mater., 8, 10.1002/adom.201901481 · DOI
  24. Lee, 2014, Plasmonic nanosnowmen with a conductive junction as highly tunable nanoantenna structures and sensitive, quantitative and multiplexable surface-enhanced Raman scattering probes, Nano Lett., 14, 6217, 10.1021/nl502541u · DOI
  25. Lee, 2021, Controlled assembly of plasmonic nanoparticles: from static to dynamic nanostructures, Adv. Mater., 33, 10.1002/adma.202007668 · DOI
  26. Li, 2022, Validation of plasma amyloid-β 42/40 for detecting Alzheimer disease amyloid plaques, Neurology, 98, e688, 10.1212/WNL.0000000000013211 · DOI
  27. Liu, 2008, MicroRNA expression profiling using microarrays, Nat. Protoc., 3, 563, 10.1038/nprot.2008.14 · DOI
  28. Liu, 2017, Plasmonic plano-semi-cylindrical nanocavities with high-efficiency local-field confinement, Sci. Rep., 7, 1
  29. Ma, 2016, Gold nanocrystals with DNA-directed morphologies, Nat. Commun., 7, 1, 10.1038/ncomms12873 · DOI
  30. Ma, 2019, Single gold-bridged nanoprobes for identification of single point DNA mutations, Nat. Commun., 10, 1, 10.1038/s41467-019-08769-y · DOI
  31. Maccaferri, 2021, Recent advances in plasmonic nanocavities for single-molecule spectroscopy, Nanoscale Adv., 3, 633, 10.1039/D0NA00715C · DOI
  32. McKhann, 2011, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's Dementia, 7, 263, 10.1016/j.jalz.2011.03.005 · DOI · Paper page
  33. Millan, 2017, Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer's disease: an integrative review, Prog. Neurobiol., 156, 1, 10.1016/j.pneurobio.2017.03.004 · DOI
  34. Mori, 2019, Extracellular miRNAs: from biomarkers to mediators of physiology and disease, Cell Metabol., 30, 656, 10.1016/j.cmet.2019.07.011 · DOI
  35. Nam, 2016, Plasmonic nanogap-enhanced Raman scattering with nanoparticles, Acc. Chem. Res., 49, 2746, 10.1021/acs.accounts.6b00409 · DOI
  36. Norton, 2014, Potential for primary prevention of Alzheimer's disease: an analysis of population-based data, Lancet Neurol., 13, 788, 10.1016/S1474-4422(14)70136-X · DOI · Paper page
  37. Polanco, 2018, Amyloid-β and tau complexity—towards improved biomarkers and targeted therapies, Nat. Rev. Neurol., 14, 22, 10.1038/nrneurol.2017.162 · DOI
  38. Prodan, 2003, A hybridization model for the plasmon response of complex nanostructures, Science, 302, 419, 10.1126/science.1089171 · DOI
  39. Rosi, 2005, Nanostructures in biodiagnostics, Chem. Rev., 105, 1547, 10.1021/cr030067f · DOI · Paper page
  40. Salmon, 2020, Light-induced coalescence of plasmonic dimers and clusters, ACS Nano, 14, 4982, 10.1021/acsnano.0c01213 · DOI
  41. Sannomiya, 2011, Single plasmonic nanoparticles for biosensing, Trends Biotechnol., 29, 343, 10.1016/j.tibtech.2011.03.003 · DOI
  42. Sharma, 2013, Exosomes function in cell–cell communication during brain circuit development, Curr. Opin. Neurobiol., 23, 997, 10.1016/j.conb.2013.08.005 · DOI
  43. Shi, 2019, Potential value of plasma amyloid-β, total tau, and neurofilament light for identification of early Alzheimer's disease, ACS Chem. Neurosci., 10, 3479, 10.1021/acschemneuro.9b00095 · DOI
  44. Shrivastava, 2011, Methods for the determination of limit of detection and limit of quantitation of the analytical methods, Chronicles Young Sci., 2, 21, 10.4103/2229-5186.79345 · DOI
  45. Soares Martins, 2021, Diagnostic and therapeutic potential of exosomes in Alzheimer's disease, J. Neurochem., 156, 162, 10.1111/jnc.15112 · DOI
  46. Song, 2011, Meta-analysis of plasma amyloid-β levels in Alzheimer's disease, J. Alzheim. Dis., 26, 365, 10.3233/JAD-2011-101977 · DOI
  47. Song, 2022, Detection of multiplex exosomal miRNAs for clinically accurate diagnosis of Alzheimer's disease using label-free plasmonic biosensor based on DNA-Assembled advanced plasmonic architecture, Biosens. Bioelectron., 199, 10.1016/j.bios.2021.113864 · DOI · Paper page
  48. Song, 2020, Real-time monitoring of distinct binding kinetics of hot-spot mutant p53 protein in human cancer cells using an individual nanorod-based plasmonic biosensor, Sensor. Actuator. B Chem., 322, 10.1016/j.snb.2020.128584 · DOI
  49. Song, 2016, Tracking of STAT3 signaling for anticancer drug-discovery based on localized surface plasmon resonance, Analyst, 141, 2493, 10.1039/C5AN02397A · DOI
  50. Song, 2020, Brain derived exosomes are a double-edged sword in Alzheimer's disease, Front. Mol. Neurosci., 13, 79, 10.3389/fnmol.2020.00079 · DOI
  51. Su, 2015, Gold nanocrystals with variable index facets as highly effective cathode catalysts for lithium–oxygen batteries, NPG Asia Mater., 7, 10.1038/am.2014.130 · DOI
  52. Sun, 2014, Casting inorganic structures with DNA molds, Science, 346, 10.1126/science.1258361 · DOI
  53. Van Giau, 2016, Emergence of exosomal miRNAs as a diagnostic biomarker for Alzheimer's disease, J. Neurol. Sci., 360, 141, 10.1016/j.jns.2015.12.005 · DOI
  54. Verberk, 2020, Combination of plasma amyloid beta (1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology, Alzheimer's Res. Ther., 12, 1, 10.1186/s13195-020-00682-7 · DOI · Paper page
  55. Wei, 2020, MicroRNAs in Alzheimer's disease: function and potential applications as diagnostic biomarkers, Front. Mol. Neurosci., 13, 160, 10.3389/fnmol.2020.00160 · DOI · Paper page
  56. Wiley, 2021, Alzheimer's disease facts and figures, Alzheimers Dement, 17, 327, 10.1002/alz.12328 · DOI
  57. Willets, 2007, Localized surface plasmon resonance spectroscopy and sensing, Annu. Rev. Phys. Chem., 58, 267, 10.1146/annurev.physchem.58.032806.104607 · DOI
  58. Wuithschick, 2015, Turkevich in new robes: key questions answered for the most common gold nanoparticle synthesis, ACS Nano, 9, 7052, 10.1021/acsnano.5b01579 · DOI
  59. Zhuang, 2011, Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain, Mol. Ther., 19, 1769, 10.1038/mt.2011.164 · DOI · Paper page

Cited by

Sorted by citations

See all 34

Metadata

Authors
Song, S., Lee, J. U., Jeon, M. J., Kim, S., Lee, C.-N., & Sim, S. J.
ORCID
Venue
Biosensors and Bioelectronics
Publisher
Elsevier BV
Published
2023-06
Volume
230
Pages
115269
ISSN
0956-5663
DOI
10.1016/j.bios.2023.115269
Cited by
34
References
5
Language
en
Licence
Funders
  • National Research Foundation of Korea (RS-2023-00208846 / NRF-2020R1A5A1018052)
  • Korea Dementia Research Center
  • Korea Ministry of Science and ICT
  • Ministry of Education (2022R1I1A3071724)
  • Korea University Anam Hospital (IRB-0201AN0286)
  • Ministry of Science, ICT and Future Planning
  • Ministry of Health and Welfare (HU21C0335)
  • Korea Health Industry Development Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review